Head-To-Head Contrast: Amarin (NASDAQ:AMRN) and BeOne Medicines (NASDAQ:ONC)

BeOne Medicines (NASDAQ:ONC – Get Free Report) and Amarin (NASDAQ:AMRN – Get Free Report) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, earnings, risk, profitability, analyst recommendations, institutional ownership and dividends.

Risk and Volatility

BeOne Medicines has a beta of 0.63, meaning that its stock price is 37% less volatile than the S&P 500. Comparatively, Amarin has a beta of 0.81, meaning that its stock price is 19% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and target prices for BeOne Medicines and Amarin, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BeOne Medicines 0 1 16 1 3.00
Amarin 2 1 0 0 1.33

BeOne Medicines presently has a consensus price target of $441.64, suggesting a potential upside of 12.97%. Amarin has a consensus price target of $13.00, suggesting a potential upside of 22.99%. Given Amarin’s higher probable upside, analysts clearly believe Amarin is more favorable than BeOne Medicines.

Institutional and Insider Ownership

48.5% of BeOne Medicines shares are owned by institutional investors. Comparatively, 22.3% of Amarin shares are owned by institutional investors. 6.2% of BeOne Medicines shares are owned by company insiders. Comparatively, 4.2% of Amarin shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares BeOne Medicines and Amarin’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
BeOne Medicines 13.86% 19.04% 10.70%
Amarin -10.87% -0.52% -0.36%

Earnings & Valuation

This table compares BeOne Medicines and Amarin”s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
BeOne Medicines $6.61 billion 6.50 $286.93 million $7.87 49.67
Amarin $176.11 million 1.26 -$38.80 million ($0.96) -11.01

BeOne Medicines has higher revenue and earnings than Amarin. Amarin is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.

Summary

BeOne Medicines beats Amarin on 13 of the 15 factors compared between the two stocks.

About BeOne Medicines

(Get Free Report)

BeOne Medicines, formerly known as BeiGene, is a global biotechnology company focused on discovering, developing, manufacturing and commercializing cancer medicines. Founded in Beijing in 2010, the company has expanded its research and commercial operations across multiple regions, including the United States, Europe and Asia. Its marketed products include Brukinsa (zanubrutinib), a targeted therapy for certain blood cancers, and Tevimbra (tislelizumab), an immunotherapy used to treat several types of cancer.

About Amarin

(Get Free Report)

Amarin Corporation plc is a biopharmaceutical company focused on cardiovascular health. Its principal product is VASCEPA, a prescription medicine containing icosapent ethyl, an omega-3 fatty acid derivative. In the United States, VASCEPA is approved for use with a statin and other measures to reduce the risk of certain cardiovascular events in eligible adults with elevated triglycerides. It is also approved as an adjunct to diet to lower triglyceride levels in adults with severe hypertriglyceridemia.

Receive News & Ratings for BeOne Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeOne Medicines and related companies with MarketBeat.com's FREE daily email newsletter.